- Regeneron (REGN) falls 5.86% premarket despite in line Q2 earnings and positive Phase 3 DME results for Eylea.
- Investors may be concerned about U.S. Eylea sales which, at $330M for the period came in just shy of Street estimates ($333M). (PR)
- Perhaps more important are the sequential growth numbers for U.S. Eylea sales: Q2, 5%; Q1, 14%; Q4 2012, 13%; Q3 2012, 26%. It appears sales growth is slowing.
- Bayer read-through on ex-U.S. Eylea sales: $96M, +47% Q/Q.
Regeneron falls on Eylea sales concerns
Aug 6 2013, 08:18 ET